Bal Pharma has fixed the record date for its FY26 final dividend at Thursday, September 17, 2026. The company will pay ₹1.20 per equity share of face value ₹10 each, representing a 12% payout on face value.

The Board of Directors approved the dividend and key dates during its meeting on August 12, 2026. The intimation was issued pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Dates and Deadlines

Shareholders must hold shares as of the record date to receive the final dividend. The same date serves as the cut-off for electronic voting eligibility for the upcoming Annual General Meeting (AGM).

The book closure period runs from September 18 to September 24, 2026, both days inclusive. Electronic voting will open on September 21 and close on September 23.

Dividend Payment Details

The final dividend will be paid on or after September 24, 2026, following approval at the AGM. Dividend income is taxable in the hands of members. The company is required to deduct tax at source (TDS) from dividends paid at prescribed rates under the Income Tax Act, 2025.

Generally, no tax will be deducted for resident individuals with valid PAN details updated in their folio/client ID records, provided the total dividend amount payable does not exceed ₹10,000. Members eligible for nil or lower TDS rates must submit requisite forms via the Registrar and Transfer Agent, MUFG Intime India Private Limited.

Shareholders are advised to ensure their bank account details in demat accounts or physical folios are updated to enable timely credit of the dividend. Post-payment, shareholders can view TDS credits in Form 168 via the income tax department’s e-filing portal.

Agenda Highlights

The AGM notice outlines several ordinary and special business items for shareholder approval.

Director Reappointment: Shareholders will vote to reappoint Mr. Ravindra Kumar Kothari (DIN: 03418320), who retires by rotation, as a Director.

Designation Changes: Two special resolutions seek approval for changes in director designations effective October 1, 2026:

• Mr. Ravindra Kumar Kothari will move from Non-Executive Director to Whole-Time Director. His remuneration is proposed at ₹22.50 lakh per annum for three years.
• Mr. Virupakshaya Himesh (DIN: 08554422) will transition from Whole-Time Director to Non-Executive Director. He will receive an honorarium of ₹2.40 lakh per annum until July 31, 2029.

Related Party Transaction: The board seeks approval to renew a contract with Messrs. Desa Marketing International, a proprietary concern of Managing Director Mr. Shailesh Siroya. The agreement covers sourcing and marketing services for three years (May 20, 2026 to May 19, 2029). The aggregate value shall not exceed ₹30 crore in one financial year. Remuneration will be 2% of domestic sourcing/marketing value and 3% of international sourcing/marketing value.

Cost Auditor Remuneration: Shareholders will ratify the remuneration of Messrs. GNV & Associates as Cost Auditors for FY27. The fee is fixed at ₹75,000 plus applicable taxes.

Bal Pharma clarified on August 25, 2026, that the tentative timeline for utilizing net proceeds from its preferential issue of convertible warrants is 18 months from the date of allotment. This disclosure aligns with the tenure of the warrants as per SEBI regulations.

The company issued the clarification under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It cited Regulation 162 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, which governs the utilization period for such instruments. The timeline is subject to receiving in-principle approval from the stock exchanges.

Regulatory Context

Bal Pharma stated that there is no change in the objects of the preferential issue or the manner of proceeds utilization. The intimation serves solely to clarify the tentative timeline based on the 18-month tenure of the convertible warrants. The company directed investors to treat this information as a formal record.

Shreepada ML, Company Secretary and Compliance Officer, signed the disclosure. The notice was sent to both the National Stock Exchange of India Limited and BSE Limited.